Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension

• Published in: Circulation (New York, N.Y.) Vol. 131; no. 2; pp. 190 - 199
• Main Authors: Kim, Jongmin, Hwangbo, Cheol, Hu, Xiaoyue, Kang, Yujung, Papangeli, Irinna, Mehrotra, Devi, Park, Hyekyung, Ju, Hyekyung, McLean, Danielle L, Comhair, Suzy A, Erzurum, Serpil C, Chun, Hyung J
• Format: Journal Article
• Language: English
• Published: United States 13.01.2015
• Subjects: Animals; Apelin; Arterioles - pathology; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelial Cells - drug effects; Endothelial Cells - pathology; Fibroblast Growth Factor 2 - biosynthesis; Fibroblast Growth Factor 2 - genetics; Hemodynamics; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylase Inhibitors - therapeutic use; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Hypertension, Pulmonary; Hypertrophy, Right Ventricular - etiology; Hypertrophy, Right Ventricular - prevention & control; Hypoxia - complications; Intercellular Signaling Peptides and Proteins - pharmacology; Male; MEF2 Transcription Factors - genetics; MEF2 Transcription Factors - physiology; MicroRNAs - biosynthesis; Monocrotaline; Pulmonary Artery - pathology; Pyrroles - pharmacology; Pyrroles - therapeutic use; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering - pharmacology; Transcription, Genetic; endothelial cells; pulmonary hypertension; transcriptional activation

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary arterioles, characterized by increased pulmonary arterial pressure and right ventricular failure. The cause of PAH is complex, but aberrant proliferation of the pulmonary artery endothelial cells (PAECs) and pulmonary ar...